Mary Miller (R-IL)
Restoring Safeguards for Dangerous Abortion Drugs Act
A Republican bill with 8 Republican cosponsors · See all 8 cosponsors
Last activity — Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
This bill, known as the "Restoring Safeguards for Dangerous Abortion Drugs Act," directs the Secretary of Health and Human Services to implement specific requirements for mifepristone. It requires the Secretary to withdraw the current risk evaluation and mitigation strategy and replace it with the strategy that was approved in June 2011. The Act also establishes a federal tort that holds certain entities liable for bodily injury or mental health harm resulting from the use of imported or transported covered medication. Additionally, it amends the Federal Food, Drug, and Cosmetic Act to include a ban on the importation of mifepristone, including via mail.
Yes
No question was scored yes.
The opposite· 3 of 5
- Scored -8
Does this make abortion easier to get?
The bill restricts abortion access by banning the importation of mifepristone via mail and mandating a different risk evaluation and mitigation strategy.
- Scored -7
Would women be better off under this?
The bill restricts access to abortion medication and creates legal liabilities related to its use.
- Scored -6
Would households on low incomes be better off under this?
Restricting the importation of medication via mail can disproportionately affect low-income individuals who rely on more affordable remote access options.
Who it would affect, and how
Potential Positive Impacts for People
-
Liability for Harm: Under Section 4, individuals who suffer bodily injury or harm to mental health (including physical, psychological, emotional, or physiological harm) attributable to the use of certain covered medication may bring civil actions against a covered entity for compensatory damages, punitive damages, and attorney's fees and costs.
-
Legal Recourse: Section 4 provides a private right of action that allows individuals to sue in a district court of the United States or a State court of competent jurisdiction.
Potential Negative Impacts for People
-
Mandated Strategy Changes: Section 3 requires the Secretary of Health and Human Services to withdraw the current risk evaluation and mitigation strategy for mifepristone and replace it with the specific strategy that was approved in June 2011.
-
Restrictions on Importation: Section 5 amends the Federal Food, Drug, and Cosmetic Act to state that no person may import the drug mifepristone into the United States, which specifically includes mailing such drugs to individuals.
-
Liability for Entities: Section 4 establishes that a covered entity—which includes telehealth providers, pharmacies, or anyone who knowingly imports or transports the medication in violation of certain laws—shall be liable to any individual who suffers bodily injury or mental health harm from the use of the medication.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Demographic And Interest Groups
- Would women be better off under this? — The bill restricts access to abortion medication and creates legal liabilities related to its use. Would households on low incomes be better off under this? — Restricting the importation of medication via mail can disproportionately affect low-income individuals who rely on more affordable remote access options.
- Healthcare
- Does this make abortion easier to get? — The bill restricts abortion access by banning the importation of mifepristone via mail and mandating a different risk evaluation and mitigation strategy.
- Social Issues And Justice
- Does this narrow the gap between how men and women are treated? — The bill creates legal and practical barriers to medication-based abortion, which disproportionately affects women's reproductive autonomy.
- Governance And Ideology
- Does this protect people from being watched or searched? — The bill's oversight of medication transport and importation may impact individual privacy in healthcare choices.
- 10/31/2025
- 1 Cosponsor added.
- 10/8/2025
- 1 Cosponsor added.
- 9/30/2025
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 6 Cosponsors added.
- Introduced in House
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
Tim BurchettRepublican · Tennessee
Sheri BiggsRepublican · South Carolina
Michael GuestRepublican · Mississippi
Andy HarrisRepublican · Maryland
Pat HarriganRepublican · North Carolina
Doug LaMalfaRepublican · California
Barry MooreRepublican · Alabama
Randy WeberRepublican · Texas